Table 1.
Ingenuity Pathway Analysis (IPA) of potential interactions among upregulated genes of ACE2-expressed-A549 and normal human bronchial epithelial (NHBE) cells infected for 24 h with severe acute respiratory syndrome coronavirus (SARS-CoV)-2 compared to a control group in the GSE147507 dataset.
| Canonical Pathways | P value | Molecules |
|---|---|---|
| Interferon Signaling | 1.58E-11 | IFI35,IFI6,IFIT1,IFIT3,IFITM1,IFITM3,ISG15,MX1,OAS1 |
| Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses | 2.82E-10 | CSF2,IL1A,IL6,IRF7,LIF,LTB,NFKB2,NOD2,OAS1,OAS2,OAS3,PTX3,TNF |
| Airway Pathology in Chronic Obstructive Pulmonary Disease | 1.86E-09 | CCL2,CCL20,CSF2,CXCL1,CXCL3,IL1A,IL23A,IL6,LIF,LTB,TNF |
| Differential Regulation of Cytokine Production in Macrophages and T Helper Cells by IL-17A and IL-17F | 7.24E-09 | CCL2,CSF2,CSF3,CXCL1,IL6,TNF |
| Differential Regulation of Cytokine Production in Intestinal Epithelial Cells by IL-17A and IL-17F | 3.80E-08 | CCL2,CSF2,CSF3,CXCL1,IL1A,TNF |
| Role of IL-17F in Allergic Inflammatory Airway Diseases | 6.31E-08 | CCL2,CSF2,CXCL1,CXCL10,IL6,MMP13,NFKB2 |
| Granulocyte Adhesion and Diapedesis | 8.91E-08 | CCL2,CCL20,CSF3,CXCL1,CXCL10,CXCL11,CXCL2,CXCL3,IL1A,MMP13,TNF |
| TREM1 Signaling | 1.12E-07 | CCL2,CSF2,CXCL3,IL6,NFKB2,NOD2,STAT5A,TNF |
| Role of IL-17A in Arthritis | 4.47E-07 | CCL2,CCL20,CXCL1,CXCL3,MMP13,NFKB2,NFKBIA |
| Altered T Cell and B Cell Signaling in Rheumatoid Arthritis | 5.13E-07 | CSF2,IL1A,IL23A,IL6,LTB,NFKB2,RELB,TNF |
| Agranulocyte Adhesion and Diapedesis | 1.15E-06 | CCL2,CCL20,CXCL1,CXCL10,CXCL11,CXCL2,CXCL3,IL1A,MMP13,TNF |
| Hematopoiesis from Pluripotent Stem Cells | 1.26E-06 | CSF2,CSF3,IL1A,IL6,IL7,LIF |
| Th17 Activation Pathway | 1.82E-06 | CCL20,CSF2,IL23A,IL6,IRAK2,NFKB2,SOCS3 |
| Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis | 1.91E-06 | CCL2,CSF2,FRZB,IL1A,IL6,IL7,IRAK2,LTB,MMP13,NFKBIA,SOCS3,TNF,WNT3A |
| Role of Cytokines in Mediating Communication between Immune Cells | 1.95E-06 | CSF2,CSF3,IL1A,IL23A,IL6,TNF |
| IL-23 Signaling Pathway | 2.29E-06 | CSF2,IL23A,NFKB2,NFKBIA,SOCS3,TNF |
| IL-17A Signaling in Gastric Cells | 2.29E-06 | CCL20,CXCL1,CXCL10,CXCL11,TNF |
| Hepatic Cholestasis | 3.24E-06 | CSF2,CYP27A1,IL1A,IL6,IRAK2,LIF,LTB,NFKB2,NFKBIA,TNF |
| TNFR2 Signaling | 5.01E-06 | BIRC3,NFKB2,NFKBIA,TNF,TNFAIP3 |
| Activation of IRF by Cytosolic Pattern Recognition Receptors | 7.76E-06 | IL6,IRF7,ISG15,NFKB2,NFKBIA,TNF |
| Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza | 8.32E-06 | CCL2,CXCL10,IL1A,IL6,TNF |
| HMGB1 Signaling | 8.51E-06 | CCL2,CSF2,IL1A,IL6,LIF,LTB,NFKB2,RND1,TNF |
| IL-9 Signaling | 9.55E-06 | BCL3,NFKB2,SOCS3,STAT5A,TNF |
| IL-17A Signaling in Fibroblasts | 1.29E-05 | CCL2,IL6,NFKB2,NFKBIA,NFKBIZ |
| Dendritic Cell Maturation | 1.55E-05 | CSF2,IL1A,IL23A,IL6,LTB,NFKB2,NFKBIA,RELB,TNF |
| Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis | 1.78E-05 | BIRC3,CSF2,FRZB,IL1A,IL6,IL7,MMP13,NFKBIA,TNF,WNT3A |
| IL-17A Signaling in Airway Cells | 1.91E-05 | CCL20,CXCL1,CXCL3,IL6,NFKB2,NFKBIA |
| IL-10 Signaling | 2.69E-05 | IL1A,IL6,NFKB2,NFKBIA,SOCS3,TNF |
| Neuroinflammation Signaling Pathway | 3.63E-05 | BIRC3,CCL2,CXCL10,GABRR2,IL6,IRAK2,IRF7,NCF1,NFKB2,PLA2G4E,TNF |
| Toll-like Receptor Signaling | 4.47E-05 | IL1A,IRAK2,NFKB2,NFKBIA,TNF,TNFAIP3 |
| Atherosclerosis Signaling | 5.62E-05 | CCL2,IL1A,IL6,MMP13,NFKB2,PLA2G4E,TNF |
| TNFR1 Signaling | 6.31E-05 | BIRC3,NFKB2,NFKBIA,TNF,TNFAIP3 |
| Systemic Lupus Erythematosus In B Cell Signaling Pathway | 8.51E-05 | CSF2,IFIT3,IL1A,IL6,IRF7,ISG15,LIF,LTB,NFKB2,TNF |
| Lymphotoxin Receptor Signaling | 1.00E-04 | CXCL1,LTB,NFKB2,NFKBIA,RELB |
| Role of IL-17A in Psoriasis | 1.38E-04 | CCL20,CXCL1,CXCL3 |
| Hematopoiesis from Multipotent Stem Cells | 1.38E-04 | CSF2,CSF3,IL7 |
| Death Receptor Signaling | 1.45E-04 | BIRC3,NFKB2,NFKBIA,PARP12,PARP9,TNF |
| Antioxidant Action of Vitamin C | 2.14E-04 | CSF2,NFKB2,NFKBIA,PLA2G4E,STAT5A,TNF |
| Hepatic Fibrosis Signaling Pathway | 2.88E-04 | CCL2,IL1A,IRAK2,MMP13,MYLK3,NCF1,NFKB2,NFKBIA,RND1,TNF,WNT3A |
| IL-17 Signaling | 5.89E-04 | CCL2,CXCL1,CXCL10,CXCL11,IL6 |
| IL-6 Signaling | 7.08E-04 | IL1A,IL6,NFKB2,NFKBIA,SOCS3,TNF |
| FAT10 Cancer Signaling Pathway | 7.08E-04 | IL6,NFKB2,NFKBIA,TNF |
| Communication between Innate and Adaptive Immune Cells | 7.94E-04 | CSF2,CXCL10,IL1A,IL6,TNF |
| Crosstalk between Dendritic Cells and Natural Killer Cells | 8.71E-04 | CSF2,IL6,LTB,NFKB2,TNF |
| Hepatic Fibrosis / Hepatic Stellate Cell Activation | 9.12E-04 | CCL2,CXCL3,IL1A,IL6,MMP13,NFKB2,TNF |
| Role of JAK family kinases in IL-6-type Cytokine Signaling | 1.35E-03 | IL6,SOCS3,STAT5A |
| Apoptosis Signaling | 1.45E-03 | BCL2A1,BIRC3,NFKB2,NFKBIA,TNF |
| PPAR Signaling | 1.66E-03 | IL1A,NFKB2,NFKBIA,STAT5A,TNF |
| Glucocorticoid Receptor Signaling | 1.82E-03 | CCL2,CSF2,CXCL3,IL6,NFKBIA,NPPA,POU2F2,STAT5A,TNF |
| Induction of Apoptosis by HIV1 | 1.95E-03 | BIRC3,NFKB2,NFKBIA,TNF |